Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius SE, with an intravenous and subcutaneous...
Digostics and AgaMatrix Team Up to Improve Gestational Diabetes Screening for UK Women via the Introduction of Oral Glucose Tolerance...
TAMPA, FL / ACCESSWIRE / April 4, 2024 / On April 1, 2024, the Florida State Supreme Court rendered two...
Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2%...
Phase 1a study of first hormone-free male pill completes enrollmentDURHAM, NC / ACCESSWIRE / March 27, 2024 / Male Contraceptive...
-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy...
Building on GE HealthCare’s legacy in medical technology, the GE HealthCare Foundation will advance equitable access to precision healthcare with...
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as...
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high...
Aiding in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic womenSAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a...
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals,...
Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified...
PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product...
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of...
OXFORD, UK / ACCESSWIRE / February 21, 2024 / Digital clinical diagnostics and diabetes home testing provider Digostics revealed today...
Department of Health and Human Services recognizes innovative program with proven outcomes for improving postpartum care for at-risk mothers in...